<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR514.html">Part 514
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 514.106  Approval of supplemental applications.
                            </h3>
                            <p class="depth1"><em>(a)(1)</em> and (2) if he/she determines that the application  satisfies the requirements of applicable statutory provisions and  regulations.</p><p class="depth1"><em>(b)</em> The Commissioner will assign a supplemental application to its  proper category to ensure processing of the application.</p><p class="depth2"><em>(1)</em> Category I. Supplements that ordinarily do not require a  reevaluation of any of the safety or effectiveness data in the parent  application. Category I supplements include the following:</p><p class="depth3"><em>(i)</em> A corporate change that alters the identity or address of the  sponsor of the new animal drug application (NADA).</p><p class="depth3"><em>(ii)</em> The sale, purchase, or construction of manufacturing  facilities.</p><p class="depth3"><em>(iii)</em> The sale or purchase of an NADA.</p><p class="depth3"><em>(iv)</em> A change in container, container style, shape, size, or  components.</p><p class="depth3"><em>(v)</em> A change in approved labeling (color, style, format, addition,  deletion, or revision of certain statements, e.g., trade name, storage,  expiration dates, etc).</p><p class="depth3"><em>(vi)</em> A change in promotional material for a prescription new animal  drug not exempted by Sec. 514.8(c)(2)(i)(C)(1) through (c)(2)(i)(C)(3).</p><p class="depth3"><em>(vii)</em> Changes in manufacturing processes that do not alter the  method of manufacture or change the final dosage form.</p><p class="depth3"><em>(viii)</em> A change in bulk drug shipments.</p><p class="depth3"><em>(ix)</em> A change in an analytical method or control procedures that do  not alter the approved standards.</p><p class="depth3"><em>(x)</em> A change in an expiration date.</p><p class="depth3"><em>(xi)</em> Addition of an alternate manufacturer, repackager, or relabeler  of the drug product.</p><p class="depth3"><em>(xii)</em> Addition of an alternate supplier of the new drug substance.</p><p class="depth3"><em>(xiii)</em> A change permitted in advance of approval as described under  Sec. 514.8(b)(3).</p><p class="depth2"><em>(2)</em> Category II. Supplements that may require a reevaluation of  certain safety or effectiveness data in the parent application. Category  II supplements include the following:</p><p class="depth3"><em>(i)</em> A change in the active ingredient concentration or composition  of the final product.</p><p class="depth3"><em>(ii)</em> A change in quality, purity, strength, and identity  specifications of the active or inactive ingredients.</p><p class="depth3"><em>(iii)</em> A change in dose (amount of drug administered per dose).</p><p class="depth3"><em>(iv)</em> A change in the treatment regimen (schedule of dosing).</p><p class="depth3"><em>(v)</em> Addition of a new therapeutic claim to the approved uses of the  product.</p><p class="depth3"><em>(vi)</em> Addition of a new or revised animal production claim.</p><p class="depth3"><em>(vii)</em> Addition of a new species.</p><p class="depth3"><em>(viii)</em> A change in the prescription or over-the-counter status of a  drug product.</p><p class="depth3"><em>(ix)</em> A change in statements regarding side effects, warnings,  precautions,   and contraindications, except the addition of approved statements to  container, package, and promotional labeling, and prescription drug  advertising.</p><p class="depth3"><em>(x)</em> A change in the drug withdrawal period prior to slaughter or in  the milk discard time.</p><p class="depth3"><em>(xi)</em> A change in the tolerance for drug residues.</p><p class="depth3"><em>(xii)</em> A change in analytical methods for drug residues.</p><p class="depth3"><em>(xiii)</em> A revised method of synthesis or fermentation of the new drug  substance.</p><p class="depth3"><em>(xiv)</em> Updating or changes in the manufacturing process of the new  drug substance and/or final dosage form (other than a change in  equipment that does not alter the method of manufacture of a new animal  drug, or a change from one commercial batch size to another without any  change in manufacturing procedure), or changes in the methods,  facilities, or controls used for the manufacture, processing, packaging,  or holding of the new animal drug (other than use of an establishment  not covered by the approval that is in effect) that give increased  assurance that the drug will have the characteristics of identity,  strength, quality, and purity which it purports or is represented to  possess.  [55 FR 46052, Nov. 1, 1990; 55 FR 49973, Dec. 3, 1990; 56 FR 12422, Mar.  25, 1991; 71 FR 74785, Dec. 13, 2006]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
